Monoclonal antibodies (mAbs) are copies of specifically designed antibodies designed to target specific antigens and associated diseases. These immunotherapy treatments can be delivered through the bloodstream and trigger the immune system to destroy the cells containing the target antigen.
It is possible to create mAbs that are specific to almost any extracellular/cell surface target through these 4 materials/processes:
Murine: from mouse proteins with the names of the treatments ending in -omab. Chimeric: part mouse and part human proteins with the names of the treatments ending in -ximab. Humanized: small parts of mouse proteins attached to human proteins with the names of the treatments ending in -zumab Human: fully human proteins with the names of the treatments ending in -umab.
Currently, mAbs therapies cover a wide range of treatments for cancer, rheumatoid arthritis, Crohn’s disease, HIV, multiple sclerosis, migraine headaches, Alzheimer’s disease, Ebola, and many other diseases.
Germfree’s bioGO® biocontainment cleanrooms are pre-designed and adaptive to provide an offsite built, process ready solution for advanced applications, available in 3 primary platform technologies: Mobile (mobile trailer/vehicle platform) Single Module (self-contained cleanroom module platform) Modular Cleanrooms (integrated, interconnected, multi-module, structural building platform)
Let's build your next project.
It is the dedication of the Germfree team that enables rapid deployment of critical infrastructure both to cutting edge research facilities and the front lines of global health security